Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis
Denosumab bei Osteoporose senkt im Vergleich zu Bisphosphonaten die Inzidenz von Typ-2-Diabetes, das Risiko für Fußulzera und die Gesamtmortalität bei Erwachsenen: Real-World-Kohortenanalyse mit systematischer Übersicht und Metaanalyse
Diabetes, Obesity and Metabolism · 2024-09 · 26 (9) · 3673-3683
DOI: 10.1111/dom.15708 ↗Auf einen Blick
Denosumab war in einer Kohortenanalyse mit geringerem Risiko für neuen Typ-2-Diabetes verbunden als Bisphosphonate. Auch Gesamtmortalität und Fußulzera traten seltener auf.
Fragestellung
Welchen Einfluss hat Denosumab im Vergleich zu Bisphosphonaten auf die Inzidenz von Typ-2-Diabetes und auf Langzeit-Outcomes bei Erwachsenen?
Methode
Retrospektive Analyse in TriNetX; 331 375 Patient:innen ohne T2D oder Krebs, 1:1-Pairing; ergänzend systematische Suche und random-effects Metaanalyse.
Ergebnisse
Denosumab vs. Bisphosphonate: neues T2D-Risiko über 5 Jahre niedriger (HR 0,83; 95 %-KI 0,78–0,88). Gesamtmortalität (0,79; 0,72–0,87) und Fußulzera (0,67; 0,53–0,86) waren ebenfalls reduziert. Metaanalyse von 4 Studien: RR 0,83 (0,79–0,87).
Schlussfolgerung der Autor:innen
Die Autoren berichten, dass Denosumab mit geringerem Risiko für incidenten T2D, Gesamtmortalität und mikrovaskuläre Komplikationen assoziiert war und dies Leitlinien zur Osteoporosebehandlung beeinflussen könnte.
Kernaussagen
- Neuer T2D-Fall: HR 0,83; 95 %-KI 0,78–0,88
- Gesamtmortalität: HR 0,79; 95 %-KI 0,72–0,87
- Fußulzera: HR 0,67; 95 %-KI 0,53–0,86
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Metaanalyse in der Zeitschrift Diabetes, Obesity and Metabolism, online erschienen am 20.06.2024. Verfasst von Alex E Henney und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK. Hauptthemen laut MEDLINE: Bone Density Conservation Agents, Denosumab, Diabetes Mellitus, Type 2, Diphosphonates. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Aim
To evaluate the impact of denosumab on (i) the incidence of type 2 diabetes (T2D), and (ii) long‐term health outcomes (microvascular [neuropathy, retinopathy, nephropathy] and macrovascular [cardiovascular disease, cerebrovascular accident] complications, and all‐cause mortality) in patients with T2D, before (iii) combining results with prior studies using meta‐analysis.
Methods
A retrospective analysis of data in a large global federated database (TriNetX; Cambridge, MA) was conducted from 331 375 patients, without baseline T2D or cancer, prescribed either denosumab (treatment, n = 45 854) or bisphosphonates (control, n = 285 521), across 83 healthcare organizations. Propensity score matching (1:1) of confounders was undertaken that resulted in 45 851 in each cohort. Secondary analysis further evaluated the impact of denosumab on long‐term health outcomes in patients with T2D. Additionally, we systematically searched prior literature that assessed the association between denosumab and T2D. Estimates were pooled using random‐effects meta‐analysis. Risk of bias and evidence quality were assessed using Cochrane‐endorsed tools.
Results
Denosumab (vs. bisphosphonates) was associated with a lower risk of incident T2D over 5 years (hazard ratio 0.83 [95% confidence interval {CI} 0.78‐0.88]). Secondary analysis showed significant risk reduction in all‐cause mortality (0.79 [0.72‐0.87]) and foot ulceration (0.67 [0.53‐0.86]). Also, pooled results from four studies (three observational, one randomized controlled trial) following meta‐analysis showed a reduced relative risk (RR [95% CI]) for incident T2D in patients prescribed denosumab (0.83 [0.79‐0.87]) (I 2 = 10.76%).
Conclusions
This is the largest cohort study to show that denosumab treatment is associated with a reduced RR of incident T2D, as well as an associated reduced RR of all‐cause mortality and microvascular complications, findings that may influence guideline development in the treatment of osteoporosis, particularly in patients who are at a high risk of T2D.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular & Metabolic Medicine, University of Liverpool, Liverpool, UK.
- Metabolism & Nutrition Research Group, Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
- Liverpool Centre for Cardiovascular Sciences, University of Liverpool and Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.
- Watford General Hospital, West Hertfordshire Teaching Hospitals NHS Foundation Trust, Hertfordshire, UK.
- Centre for Musculoskeletal Research, Faculty of Biology Medicine and Health, The University of Manchester, Manchester, UK.
- Centre for Biomechanics and Rehabilitation Technologies, Staffordshire University, Stoke-on-Trent, UK.
ORCID-Profile: Alex E Henney
Zitieren
APA
Henney, A. E., Riley, D. R., O'Connor, B., Hydes, T. J., Anson, M., Zhao, S. S., Alam, U., & Cuthbertson, D. J. (2024). Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis. Diabetes, Obesity and Metabolism, 26(9), 3673-3683. https://doi.org/10.1111/dom.15708
Vancouver
Henney AE, Riley DR, O'Connor B, Hydes TJ, Anson M, Zhao SS, et al. Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis. Diabetes, Obesity and Metabolism. 2024;26(9):3673-3683. doi:10.1111/dom.15708
BibTeX
@article{Henney2024,
author = {Henney, Alex E and Riley, David R and O'Connor, Ben and Hydes, Theresa J and Anson, Matthew and Zhao, Sizheng Steven and Alam, Uazman and Cuthbertson, Daniel J},
title = {Denosumab, for osteoporosis, reduces the incidence of type 2 diabetes, risk of foot ulceration and all‐cause mortality in adults, compared with bisphosphonates: An analysis of real‐world, cohort data, with a systematic review and meta‐analysis},
journal = {Diabetes, Obesity and Metabolism},
year = {2024},
volume = {26},
number = {9},
pages = {3673--3683},
doi = {10.1111/dom.15708}
}
EUVIMED